Improving the treatment of mucosal and dermal diseases with the power of glycomics

Protecting the gastrointestinal (GI) tract from cancer therapy

Side effects of radiation and chemotherapy include gut epithelial cell death and gut barrier damage, known as GI mucositis. This damage initiates a cycle of inflammation and infection, and may lead to sepsis and death. Patients with GI mucositis may experience symptoms that include inability to swallow, ulcerations of the GI tract, bleeding, diarrhea, stool incontinence, or in severe cases, GI tissue necrosis. Synedgen is developing first-in-class cancer adjunctive therapeutics to repair GI mucositis injury, promote healing, and restore a healthy microbiome. Our lead drug, SYGN305, is being developed to help patients tolerate cancer therapy by managing acute GI side effects and preventing lasting damage to the GI tract.

Learn more about SYGN305

Our unique, proprietary glycomics platform

Targeted therapies Rapid bench-to-bedside translation Excellent safety profiles Scalable GMP production

Synedgen designs glycopolymers to protect, repair and restore the body’s protective barriers. Applications cover a broad span of clinical modalities. Synedgen has previously developed therapeutics with unprecedented safety profiles in pulmonary, oral, wound, and ophthalmic applications.

Learn more


October 19, 2021

SWM International’s Scapa Healthcare Business Signs Exclusive Technology Licensing Agreement for Novel Wound Care Technology with Synedgen, Inc.
Read More

August 5, 2021

Synedgen Initiates Clinical Trial Assessing Combination of SynePure and Catasyn for the Treatment of Partial Thickness Burns
Read More

February 18, 2021

Synedgen Appoints Industry Veteran Dennis Fenton, Ph.D., to Board of Directors
Read More